These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 30190343

  • 1. ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study.
    Strati P, Fanale MA, Oki Y, Turturro F, Fayad LE, Bartlett NL, Gladstone DE, Kasamon YL, Portlock CS, Wilson WH, Goy A, Younes A, Lee HJ.
    Haematologica; 2019 Feb; 104(2):e65-e67. PubMed ID: 30190343
    [No Abstract] [Full Text] [Related]

  • 2. Phase II study of ABV (doxorubicin with increased dose, bleomycin and vinblastine) therapy in newly diagnosed advanced-stage Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG9705).
    Ogura M, Itoh K, Ishizawa K, Kobayashi Y, Tobinai K, Kinoshita T, Hirano M, Ueda R, Shibata T, Nakamura S, Tsukasaki K, Hotta T, Shimoyama M, Morishima Y, Lymphoma Study Group (LSG) of Japan Clinical Oncology Group (JCOG).
    Leuk Lymphoma; 2013 Jan; 54(1):46-52. PubMed ID: 22712838
    [Abstract] [Full Text] [Related]

  • 3. Outcome of pediatric advanced Hodgkin lymphoma treated with ABVD and predictors of inferior survival: a multicenter study of 186 patients.
    Bhethanabhotla S, Jain S, Kapoor G, Mahajan A, Chopra A, Vishnubhatla S, Bakhshi S.
    Leuk Lymphoma; 2017 Jul; 58(7):1617-1623. PubMed ID: 27919174
    [Abstract] [Full Text] [Related]

  • 4. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly.
    Stamatoullas A, Brice P, Bouabdallah R, Mareschal S, Camus V, Rahal I, Franchi P, Lanic H, Tilly H.
    Br J Haematol; 2015 Jul; 170(2):179-84. PubMed ID: 25891777
    [Abstract] [Full Text] [Related]

  • 5. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma.
    Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter JN, Horning SJ, Dar AR, Shustik C, Stewart DA, Crump M, Djurfeldt MS, Chen BE, Shepherd LE, NCIC Clinical Trials Group, Eastern Cooperative Oncology Group.
    N Engl J Med; 2012 Feb 02; 366(5):399-408. PubMed ID: 22149921
    [Abstract] [Full Text] [Related]

  • 6. Early intensification treatment approach in advanced-stage Hodgkin lymphoma.
    Borchmann P.
    Hematol Oncol Clin North Am; 2014 Feb 02; 28(1):65-74. PubMed ID: 24287068
    [Abstract] [Full Text] [Related]

  • 7. ABVD vs. radiotherapy in early stage Hodgkin's lymphoma: A critical look at the NCIC HD.6 trial.
    Wenz F, Abo-Madyan Y, Welzel G, Giordano FA.
    Strahlenther Onkol; 2012 Aug 02; 188(8):649-52. PubMed ID: 22729282
    [No Abstract] [Full Text] [Related]

  • 8. Intermediate stage Hodgkin lymphoma in partial remission after three or four courses of doxorubicin, bleomycin, vinblastine dacarbazine: no benefit of one course of intensive chemotherapy before irradiation.
    Arakelyan N, Jais JP, Tomowiack C, Colombat P, Berthou C, Desablens B, Moles-Moreau MP, Gastinne T, Quittet P, Casassus P, Le Pourhiet-Le Mevel A, Ghandour C, Brière J, Colonna P, Andrieu JM.
    Leuk Lymphoma; 2013 Jan 02; 54(1):76-82. PubMed ID: 22680774
    [Abstract] [Full Text] [Related]

  • 9. Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL).
    Zallio F, Tamiazzo S, Monagheddu C, Merli F, Ilariucci F, Stelitano C, Liberati AM, Mannina D, Vitolo U, Angelucci E, Rota Scalabrini D, Vallisa D, Bellei M, Bari A, Ciccone G, Salvi F, Levis A.
    Br J Haematol; 2016 Mar 02; 172(6):879-88. PubMed ID: 26763986
    [Abstract] [Full Text] [Related]

  • 10. Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial.
    Danilov AV, Li H, Press OW, Shapira I, Swinnen LJ, Noy A, Reid E, Smith SM, Friedberg JW.
    Leuk Lymphoma; 2017 Feb 02; 58(2):461-465. PubMed ID: 27386786
    [No Abstract] [Full Text] [Related]

  • 11. Children and Adolescent Hodgkin Lymphoma in Argentina: Long-term Results After Combined ABVD and Restricted Radiotherapy.
    Zubizarreta PA, Alfaro E, Guitter M, Sanchez La Rosa C, Galluzzo ML, Millán N, Fiandrino F, Felice MS.
    J Pediatr Hematol Oncol; 2017 Nov 02; 39(8):602-608. PubMed ID: 28902084
    [Abstract] [Full Text] [Related]

  • 12. Reduced versus full doses of irradiation after 3 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine in early stage Hodgkin lymphomas: results of a randomized trial.
    Arakelyan N, Jais JP, Delwail V, Brière J, Moles-Moreau MP, Sénécal D, Berthou C, Desablens B, Colonna P, Andrieu JM, GOELAMS Hodgkin Lymphoma Network.
    Cancer; 2010 Sep 01; 116(17):4054-62. PubMed ID: 20564152
    [Abstract] [Full Text] [Related]

  • 13. High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan.
    Kedmi M, Apel A, Davidson T, Levi I, Dann EJ, Polliack A, Ben-Bassat I, Nagler A, Avigdor A.
    Acta Haematol; 2016 Sep 01; 135(3):156-61. PubMed ID: 26588173
    [Abstract] [Full Text] [Related]

  • 14. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
    Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, Vitolo U, Pulsoni A, Liberati AM, Specchia G, Valagussa P, Rossi A, Zaja F, Pogliani EM, Pregno P, Gotti M, Gallamini A, Rota Scalabrini D, Bonadonna G, Gianni AM, Michelangelo Foundation, Gruppo Italiano di Terapie Innovative nei Linfomi, Intergruppo Italiano Linfomi.
    N Engl J Med; 2011 Jul 21; 365(3):203-12. PubMed ID: 21774708
    [Abstract] [Full Text] [Related]

  • 15. Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy.
    Chand VK, Link BK, Ritchie JM, Shannon M, Wooldridge JE.
    Leuk Lymphoma; 2006 Apr 21; 47(4):657-63. PubMed ID: 16690524
    [Abstract] [Full Text] [Related]

  • 16. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
    Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP, Peterson BA.
    J Clin Oncol; 2003 Feb 15; 21(4):607-14. PubMed ID: 12586796
    [Abstract] [Full Text] [Related]

  • 17. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.
    Straus DJ, Długosz-Danecka M, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Ramchandren R, Zinzani PL, Hutchings M, Connors JM, Radford J, Munoz J, Kim WS, Advani R, Ansell SM, Younes A, Miao H, Liu R, Fenton K, Forero-Torres A, Gallamini A.
    Blood; 2020 Mar 05; 135(10):735-742. PubMed ID: 31945149
    [Abstract] [Full Text] [Related]

  • 18. Granulocyte colony-stimulating factor as secondary prophylaxis of febrile neutropenia in the management of advanced-stage Hodgkin lymphoma treated with adriamycin, bleomycin, vinblastine and dacarbazine chemotherapy: a decision analysis.
    Graczyk J, Cheung MC, Buckstein R, Chan K.
    Leuk Lymphoma; 2014 Jan 05; 55(1):56-62. PubMed ID: 23597142
    [Abstract] [Full Text] [Related]

  • 19. Bilateral sudden hearing loss following ABVD protocol.
    Tazi I, Nafil H, Mahmal L.
    J Cancer Res Ther; 2014 Jan 05; 10(1):212. PubMed ID: 24762521
    [No Abstract] [Full Text] [Related]

  • 20. A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma.
    Russo F, Corazzelli G, Frigeri F, Capobianco G, Aloj L, Volzone F, De Chiara A, Bonelli A, Gatani T, Marcacci G, Donnarumma D, Becchimanzi C, de Lutio E, Ionna F, De Filippi R, Lastoria S, Pinto A.
    Br J Haematol; 2014 Jul 05; 166(1):118-29. PubMed ID: 24673727
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.